TY - JOUR
T1 - Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer
AU - Scilipoti, Pietro
AU - Longoni, Mattia
AU - de Angelis, Mario
AU - Zaurito, Paolo
AU - Ślusarczyk, Aleksander
AU - Soria, Francesco
AU - Pradere, Benjamin
AU - Krajewski, Wojciech
AU - D'Andrea, David
AU - Mari, Andrea
AU - del Giudice, Francesco
AU - Pichler, Renate
AU - Subiela, José Daniel
AU - Marcq, Gautier
AU - Gallioli, Andrea
AU - Afferi, Luca
AU - Mastroianni, Riccardo
AU - Simone, Giuseppe
AU - Albisinni, Simone
AU - Mertens, Laura S.
AU - Laukhtina, Ekaterina
AU - Oberneder, Katharina
AU - Rodríguez Elena, José Luis
AU - Aranda, Javier
AU - Puentedura, Alfonso Lafuente
AU - Caño Velasco, Jorge
AU - Contieri, Roberto
AU - Hurle, Rodolfo
AU - Mori, Keiichiro
AU - Radziszewski, Piotr
AU - the European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group
AU - Shariat, Shahrokh F.
AU - Gontero, Paolo
AU - Necchi, Andrea
AU - Rouprêt, Morgan
AU - Montorsi, Francesco
AU - Salonia, Andrea
AU - Briganti, Alberto
AU - Moschini, Marco
N1 - Publisher Copyright:
© 2025 BJU International.
PY - 2025/7
Y1 - 2025/7
N2 - Objective: To assess the oncological outcomes of patients with high-risk (HR) and very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette–Guérin (BCG) instillations from a contemporary European multicentre cohort. Patients and Methods: We conducted a retrospective analysis of 1491 patients diagnosed with HR- or VHR-NMIBC from a European multicentre database between 2015 and 2024. Patients were included if they received either upfront RC or at least five doses of BCG. A 1:1 propensity score matching (PSM) according to clinically relevant variables was applied. Progression was defined as muscle-invasive or metastatic disease. Cumulative incidence plots and multivariable competing risk regression models addressing cancer-specific mortality (CSM) were fitted. Results: Among the 1221 patients with HR- (n = 1221 [90%]) or VHR-NMIBC (n = 121 [10%]), 87 (7.1%) underwent upfront RC. The median follow-up was 2.6 years. After PSM (87 vs 87 patients), the 5-year CSM rate was similar in patients treated with BCG (13%) vs their upfront RC counterparts (16%) (hazard ratio: 1.77, 95% confidence interval [CI] 0.66–4.73; P = 0.3). Of the 1134 patients who initially received BCG, 73 (6.6%) eventually required delayed RC, with 34 (47%) progressing to muscle-invasive bladder cancer before delayed RC. The 3-year CSM rate was comparable in upfront RC (13%) vs delayed RC (11%) among non-progressing patients (P = 0.3). However, patients who progressed before delayed RC had worse 3-year CSM relative to those who did not (13% vs 31%, hazard ratio: 0.32, 95% CI 0.13–0.83; P = 0.018). Conclusion: Within a European cohort of patients with HR- and VHR-NMIBC, upfront RC was rarely performed. Patients treated with BCG did not exhibit a CSM disadvantage relative to their upfront RC counterparts. After matching, long-term CSM was similar between BCG therapy and upfront RC. Delayed RC, led to worse outcomes if performed after progression, but matched upfront RC when performed before progression, underscoring importance of timely surgery.
AB - Objective: To assess the oncological outcomes of patients with high-risk (HR) and very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette–Guérin (BCG) instillations from a contemporary European multicentre cohort. Patients and Methods: We conducted a retrospective analysis of 1491 patients diagnosed with HR- or VHR-NMIBC from a European multicentre database between 2015 and 2024. Patients were included if they received either upfront RC or at least five doses of BCG. A 1:1 propensity score matching (PSM) according to clinically relevant variables was applied. Progression was defined as muscle-invasive or metastatic disease. Cumulative incidence plots and multivariable competing risk regression models addressing cancer-specific mortality (CSM) were fitted. Results: Among the 1221 patients with HR- (n = 1221 [90%]) or VHR-NMIBC (n = 121 [10%]), 87 (7.1%) underwent upfront RC. The median follow-up was 2.6 years. After PSM (87 vs 87 patients), the 5-year CSM rate was similar in patients treated with BCG (13%) vs their upfront RC counterparts (16%) (hazard ratio: 1.77, 95% confidence interval [CI] 0.66–4.73; P = 0.3). Of the 1134 patients who initially received BCG, 73 (6.6%) eventually required delayed RC, with 34 (47%) progressing to muscle-invasive bladder cancer before delayed RC. The 3-year CSM rate was comparable in upfront RC (13%) vs delayed RC (11%) among non-progressing patients (P = 0.3). However, patients who progressed before delayed RC had worse 3-year CSM relative to those who did not (13% vs 31%, hazard ratio: 0.32, 95% CI 0.13–0.83; P = 0.018). Conclusion: Within a European cohort of patients with HR- and VHR-NMIBC, upfront RC was rarely performed. Patients treated with BCG did not exhibit a CSM disadvantage relative to their upfront RC counterparts. After matching, long-term CSM was similar between BCG therapy and upfront RC. Delayed RC, led to worse outcomes if performed after progression, but matched upfront RC when performed before progression, underscoring importance of timely surgery.
KW - Bacillus Calmette–Guérin
KW - high risk
KW - non-muscle-invasive bladder cancer
KW - survival analysis
KW - upfront radical cystectomy
KW - very high risk
UR - https://www.scopus.com/pages/publications/85219190213
U2 - 10.1111/bju.16675
DO - 10.1111/bju.16675
M3 - Article
C2 - 39967051
SN - 1464-4096
VL - 136
SP - 47
EP - 54
JO - BJU international
JF - BJU international
IS - 1
ER -